Our analysis of the potential role of PRDX1 in clinical therapeutic intervention revealed that HCC patients with high PRDX1 expression were susceptible to immunotherapy agents such as sorafenib, JAK inhibitor, IRAK4 inhibitor, and TGF-β Receptor I/II inhibitor, SKY inhibitor, and ERK inhibitor have a high degree of sensitivity. Here, IRAK4 is linked to hepatocellular carcinoma.